Dr. Christopher M. Gallagher, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
6900 Georgia Ave Nw, Hematology-oncology Service, Bldg 2. Ward 78
Washington, DC 20307
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 199
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
VA license 0101052887
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tidalhealth Peninsula Regional, Inc Salisbury, MD
- Tidalhealth Nanticoke, Inc. Seaford, DE
Medical groups
- Tidalhealth Specialty Care LLC (398 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 199
- Services billed
- 606
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 238 | 84 |
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 108 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Washington, DC | 56 |
| Letrozole Other prescribers in Washington, DC | 52 |
| Exemestane | 16 |
| Eliquis (apixaban) Other prescribers in Washington, DC | 15 |
| Alendronate Sodium Other prescribers in Washington, DC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 26 payments worth $3,812 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $3,320 |
|---|---|
| Pfizer Inc. | $67.13 |
| Astellas Pharma US Inc | $52.66 |
| Regeneron Healthcare Solutions, Inc. | $52.44 |
| Gilead Sciences, Inc. | $42.13 |
| Array Biopharma Inc | $42.02 |
| Daiichi Sankyo Inc. | $39.18 |
| Merck Sharp & Dohme LLC | $36.99 |
| Consulting Fee | $3,280 |
|---|---|
| Food and Beverage | $502 |
| Education | $30.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
| Pfizer Inc. Sep 16, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $134,678 in research payments for these studies, mostly to the institutions running them.
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo Inc. · Completed · NCT03529110 - DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo Inc. · Completed · NCT03523585 - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.